Phenibut (β-Phenyl-γ-Aminobutyric Acid): an Easily Obtainable “Dietary Supplement” With Propensities for Physical Dependence and Addiction
- 168 Downloads
Purpose of Review
Phenibut (β-phenyl-γ-aminobutyric acid) is a psychoactive GABA analogue currently being marketed online as an anxiolytic and nootropic dietary supplement. Its use is growing in popularity, but its pharmacological activity is well beyond that of a conventional nutritional supplement, and similar to that of a prescription strength sedative. This review will focus on the potential adversities of phenibut use and will discuss what treatment options may be beneficial to afflicted patients.
Over the last several years, multiple case reports have highlighted phenibut’s potential to produce the conditions of physical dependence, withdrawal, and addiction. In cases involving intoxication, patients have presented with a varying degree of mental status changes, from being minimally responsive to manifesting symptoms of an agitated delirium.
Phenibut is a potent psychoactive substance with GABAB agonist properties, which is emerging as a drug of misuse through growing internet sales. Its marketing as a “dietary supplement” is inaccurate and misleading, given its pharmacological profile and ability to induce the physiological changes associated with withdrawal and physical dependence.
KeywordsPhenibut Nootropic New psychoactive substance Baclofen GABAB agonist Dietary supplement
The author and publisher would like to thank Dr. Patricia Ordorica, MD, for reviewing this manuscript.
Compliance with Ethical Standards
Conflict of Interest
Edward A. Jouney declares no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.• Owen DR, Wood DM, Archer JR, Dargan PI. Phenibut (4-amino-3-phenyl-butyric acid): availability, prevalence of use, desired effects and acute toxicity. Drug Alcohol Rev. 2016;35(5):591–6. https://doi.org/10.1111/dar.12356 Internet availability of phenibut in the UK is reviewed, in addition to a analysis of the symptoms patients may be attempting to self-soothe. This highlights the ease of availablity through multiple online vendors, and providers a glimpse into what may be driving patients to use phenibut. CrossRefPubMedGoogle Scholar
- 4.EMCDDA-Europol. New drugs in Europe, 2012, EMCDDA-Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA. Luxembourg: Publications Office of the European Union; 2013.Google Scholar
- 5.UNODC: United Nations Office on Drugs and Crime. UNODC Early Warning Advisory (EWA) on New Psychoactive Substances (NPS). https://www.unodc.org/LSS/Home/NPS. Accessed 10 Sept 2018.
- 6.UNODC: United Nations Off ice on Drugs and Crime. Global Smart Update. Understanding the synthetic drug market: the NPS factor. Volume 19, March. https://www.unodc.org/documents/scientific/Global_Smart_Update_2018_Vol.19.pdf.
- 7.Mellor, L. What is Phenibut? The cosmonaut drug that may have caused a school overdose. ABC News. 22 Feb 2019 11:54pm. https://www.abc.net.au/news/2018-02-23/what-is-phenibut-the-drug-suspected-in-school-overdose/9475814. Accessed 10 Sept 2018.
- 9.U.S Food and Drug Administration. Dietary Supplement Health and Education Act of 1994. Public Law 103-417, 103rd Congress. http://dshedu.whnlive.com/DSHEA_Legal/dshea.html. Accessed 10 Sept 2018.
- 10.FDA. Dietary supplements: what you need to know. https://www.fda.gov/food/resourcesforyou/consumers/ucm109760.htm. Accessed 11 Sept 2018; 2018.
- 11.FDA. FDA 101: dietary supplements. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm050803.htm. Accessed 13 Sept 2018; 2018.
- 14.Zvejniece L, Vavers E, Svalbe B, Veinberg G, Rizhanova K, Liepins V, et al. R-phenibut binds to the alpha2-delta subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects. Pharmacol Biochem Behav. 2015;137:23–9. https://doi.org/10.1016/j.pbb.2015.07.014.
- 21.• Brunner E, Levy R. Case report of physiologic phenibut dependence treated with a phenobarbital taper in a patient being treated with buprenorphine. J Addict Med. 2017;11(3):239–40. https://doi.org/10.1097/ADM.0000000000000303 A case of phenibut addiction is described, which is seldom published, and use of phenobarbital as a detoxification strategy is implemented with success. CrossRefPubMedGoogle Scholar
- 23.•• Samokhvalov AV, Paton-Gay CL, Balchand K, Rehm J. Phenibut dependence. BMJ Case Rep. 2013;2013:bcr2012008381. https://doi.org/10.1136/bcr-2012-008381 The use of baclofen in the detoxification off phenibut is described here, and a several week tapering protocol with dosage recommendations is provided. This is only one of a few papers which provides clinical recommendations for managing phenibut discontinuation and withdrawal. CrossRefPubMedPubMedCentralGoogle Scholar
- 25.El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, et al. Characteristics of tianeptine exposures reported to the National Poison Data System - United States, 2000-2017. MMWR Morb Mortal Wkly Rep. 2018;67(30):815–8. https://doi.org/10.15585/mmwr.mm6730a2. CrossRefPubMedPubMedCentralGoogle Scholar